logo-loader

Shares in Edge Therapeutics rocket on results presentation news

Last updated: 02:20 11 Feb 2016 AEDT, First published: 21:20 10 Feb 2016 AEDT

cancercell_56bb569d2f5d6
Edge uses microparticles to treat patients who have had a rare type of stroke

Shares in biotech firm Edge Therapeutics (NASDAQ:EDGE) rocketed as it announced the full set of results from its North American Phase I/II study of its EG-1962 treatment for NEWTON will be presented at the International Stroke Conference 2016.

The event will be held on February 17-19 at the Los Angeles Convention Center.

Shares in the company jumped around 13.5% to US$7.72 on the news.

The clinical-stage biotech firm is developing novel hospital-based therapies in the management of acute, life-threatening conditions.

Edge's lead product candidate, EG-1962, is in development to treat patients who have suffered a rare type of stroke known as aneurysmal subarachnoid haemorrhage, which can be the results of a ruptured brain aneurysm.

The data is from a Phase I/II trial, which, simply put was used to test whether microparticles can be used to treat patients who have suffered from the rare type of stroke

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

8 hours, 29 minutes ago